Therapeutic approaches to subcutaneous mycoses

American Journal of Clinical Dermatology

Volumn 4, Issue 8, 2003, Pages 537-543

  Koga, Tetsuya ^a   Matsuda, Tetsuo ^a   Matsumoto, Tadahiko ^b   Furue, Masutaka ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b Toshiba General Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; POTASSIUM IODIDE; TERBINAFINE;

BLOOD; CHROMOMYCOSIS; CLINICAL FEATURE; COLLETOTRICHUM; DERMIS; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DRUG TOLERABILITY; FONSECAEA; FUNGUS CULTURE; HUMAN; HUMAN TISSUE; HYALOHYPHOMYCOSIS; HYPERTHERMIC THERAPY; IMMUNE DEFICIENCY; LYMPH FLOW; MYCETOMA; MYCOSIS; NEPHROTOXICITY; PHAEOHYPHOMYCOSIS; PRIORITY JOURNAL; RELAPSE; REVIEW; SIDE EFFECT; SKIN SURGERY; SPOROTHRIX SCHENCKII; SPOROTRICHOSIS; SUBCUTANEOUS TISSUE; TROPICS;

ANTIFUNGAL AGENTS; DERMATOMYCOSES; HUMANS; SPOROTRICHOSIS;

EID: 0042664123     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200304080-00003     Document Type: Review

References (43)

1. Matsumoto T, Matsuda T. Sporotrichosis, chromoblastomycosis, and phaeohyphomycosis: diagnosis and treatment. Dermatol Ther 1997; 3: 91-6
2. Liu X, Lin X. A case of cutaneous disseminated sporotrichosis. J Dermatol 2001; 28: 95-9
3. Shaw JC, Levinson W, Montanaro A. Sporotrichosis in the acquired immunodeficiency syndrome. J Am Acad Dermatol 1989; 21: 1145-7
4. Fitzpatrick JE, Eubanks S. Acquired immunodeficiency syndrome presenting as disseminated cutaneous sporotrichosis. Int J Dermatol 1988; 27: 406-7
5. Gordhan A, Ramdial PK, Morar N, et al. Disseminated cutaneous sporotrichosis: a marker of osteoarticular sporotrichosis masquerading as gout. Int J Dermatol 2001; 40: 717-9
6. Kauffman CA, Hajjeh R, Chapman SW. Practice guidelines for the management of patients with sporotrichosis. Clin Infect Dis 2000; 30: 684-7
7. Sharkey-Mathis PK, Kauffman CA, Graybill JR, et al. Treatment of sporotrichosis with itraconazole. Am J Med 1993; 95: 279-85
8. Kauffman CA. Old and new therapies for sporotrichosis. Clin Infect Dis 1995; 21: 981-5
9. Restrepo A, Robledo J, Gomez I, et al. Itraconazole therapy in lymphangitic and cutaneous sporotrichosis. Arch Dermatol 1986; 122: 413-7
10. Conti Diaz IA, Civila E, Gezuele E, et al. Treatment of human cutaneous sporotrichosis with itraconazole. Mycoses 1992; 35: 153-6
11. Kauffman CA, Pappas PG, McKinsey DS, et al. Treatment of lymphocutaneous and visceral sporotrichosis with fluconazole. Clin Infect Dis 1996; 22: 46-50
12. Diaz M, Negroni R, Montero-Gei F, et al. A pan-American 5-year study of fluconazole therapy for deep mycoses in the immunocompetent host. Clin Infect Dis 1992; 14 Suppl. 1: S68-76
13. Castro LG, Belda Jr W, Cuce LC, et al. Successful treatment of sporotrichosis with oral fluconazole: a report of three cases. Br J Dermatol 1993; 128: 352-6
14. Habte-Gabr E, Walsh W. Cutaneous sporotrichosis: the old iodide treatment remains effective. Clin Microbiol Infect 2000; 6: 53-5
15. Lesher Jr JL, Fitch MH, Dunlap DB. Subclinical hypothyroidism during potassium iodide therapy for lymphocutaneous sporotrichosis. Cutis 1994; 53: 128-30
16. Vandervee EE. Sporotrichosis in pregnancy. Cutis 1982; 30: 761-3
17. Hay RJ. Therapeutic potential of terbinafine in subcutaneous and systemic mycoses. Br J Dermatol 1999; 141 Suppl. 56: 36-40
18. Perez A. Terbinafine: broad new spectrum of indications in several subcutaneous and systemic and parasitic diseases. Mycoses 1999; 42 Suppl. 2: 111-4
19. Hull PR, Vismer HF. Treatment of cutaneous sporotrichosis with terbinafine. Br J Dermatol 1992; 126 Suppl. 39: 51-5
20. Pappas PG, Bustamante B, Nolasco D, et al. Treatment of lymphocutaneous sporotrichosis with terbinafine: results of randomized double-blind trial [abstract 648]. 39th Annual Meeting of the Infectious Diseases Society of America; 2001 Oct 25-28, San Francisco
21. Hiruma M, Kawada A, Noguchi H, et al. Hyperthermic treatment of sporotrichosis: experimental use of infrared and far infrared rays. Mycoses 1992; 35: 293-9
22. Matsumoto T. Chromoblastomycosis and phaeohyphomycosis. In: Guerrant RL, Walker DH, Weller PF, et al., editors. Tropical infectious diseases: principles, pathogens, and practice. Philadelphia (PA): Churchill Livingstone, 1999: 621-5
23. Restrepo A. Treatment of tropical mycoses. J Am Acad Dermatol 1994; 31: S91-102
24. Minotto R, Bernardi CD, Mallmann LF, et al. Chromoblastomycosis: a review of 100 cases in the state of Rio Grande do Sul, Brazil. J Am Acad Dermatol 2001; 44: 585-92
25. Dixon DM, Polak-Wyss A. The medically important dematiaceous fungi and their identification. Mycoses 1991; 34: 1-18
26. Queiroz-Telles F, Purim KS, Fillus JN, et al. Itraconazole in the treatment of chromoblastomycosis due to Fonsecaea pedrosoi. Int J Dermatol 1992; 31: 805-12
27. Esterre P, Inzan CK, Ramarcel ER, et al. Treatment of chromomycosis with terbinafine: preliminary results of an open pilot study. Br J Dermatol 1996; 134 Suppl. 46: S33-6
28. Tagami H, Ginoza M, Imaizumi S, et al. Successful treatment of chromoblastomycosis with topical heat therapy. J Am Acad Dermatol 1984; 10: 615-9
29. Matsumoto T, Ajello L, Matsuda T, et al. Developments in hyalohyphomycosis and phaeohyphomycosis. J Med Vet Mycol 1994; 32 Suppl. 1: S329
30. Bittencourt AL, Machado PR. Araujo MG. Subcutaneous phaeohyphomycosis caused by Cyphellophora pluriseptata. Eur J Dermatol 2002; 12: 103-6
31. Matsumoto T. Wangiella dermatitidis infections: a paradigm of the opportunistic mycoses caused by black yeasts and moulds. Korean J Med Mycol 2000; 5: 45-50
32. Gerdsen R, Uerlich M, De Hoog GS, et al. Sporotrichoid phaeohyphomycosis due to Alternaria infectoria. Br J Dermatol 2001; 145: 484-6
33. Matsumoto T, Ajello L. Agents of phaeohyphomycosis. In: Collier L, Balows A, Sussman M, editors. Topley & Wilson's microbiology and microbial infections. 9th ed. Vol. 4. London: Arnold, 1998: 503-24
34. Xu X, Low DW, Palevsky HI, et al. Subcutaneous phaeohyphomycotic cysts caused by Exophiala jeanselmei in a lung transplant patient. Dermatol Surg 2001; 27: 343-6
35. Gugnani HC, Sood N, Singh B, et al. Case report: subcutaneous phaeohyphomycosis due to Cladosporium cladosporioides. Mycoses 2000; 43: 85-7
36. Vieira MR, Milheiro A, Pacheco FA. Phaeohyphomycosis due to Cladosporium cladosporioides. Med Mycol 2001; 39: 135-7
37. Sharkey PK, Graybill JR, Rinaldi MG, et al. Itraconazole treatment of phaeohyphomycosis. J Am Acad Dermatol 1990; 23: 577-86
38. Clancy CJ, Wingard JR, Hong Nguyen M. Subcutaneous phaeohyphomycosis in transplant recipients: review of the literature and demonstration of in vitro synergy between antifungal agents. Med Mycol 2000; 38: 169-75
39. Caligiorne RB, Resende MA, Melillo PH, et al. In vitro susceptibility of chromoblastomycosis and phaeohyphomycosis agents to antifungal drugs. Med Mycol 1999; 37: 405-9
40. O'Quinn RP, Hoffmann JL, Boyd AS. Colletotrichum species as emerging opportunistic fungal pathogens: a report of 3 cases of phaeohyphomycosis and review. J Am Acad Dermatol 2001; 45: 56-61
41. Poncio Mendes R, Negroni R, Bonifaz A, et al. New aspects of some endemic mycoses. Med Mycol 2000; 38 Suppl. 1: 237-41
42. Bernstein EF, Schuster MG, Stieritz DD, et al. Disseminated cutaneous Pseudallescheria boydii. Br J Dermatol 1995; 132: 456-60
43. Ginter G, Petutschnig B, Pierer G, et al. Atypical cutaneous pseudallescheriosis refractory to antifungal agents. Mycoses 1999; 42: 507-11